CY1123952T1 - Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α - Google Patents

Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α

Info

Publication number
CY1123952T1
CY1123952T1 CY20201100781T CY201100781T CY1123952T1 CY 1123952 T1 CY1123952 T1 CY 1123952T1 CY 20201100781 T CY20201100781 T CY 20201100781T CY 201100781 T CY201100781 T CY 201100781T CY 1123952 T1 CY1123952 T1 CY 1123952T1
Authority
CY
Cyprus
Prior art keywords
antibodies
affinity chromatography
isolation
purification
protein
Prior art date
Application number
CY20201100781T
Other languages
English (en)
Inventor
Robert Hickman
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1123952T1 publication Critical patent/CY1123952T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Εδώ αποκαλύπτονται μέθοδοι για την απομόνωση και τον καθαρισμό αντισωμάτων αντι-ΙL-13 όπου η χρήση ενός σταδίου χρωματογραφικής συγγένειας έχει ως αποτέλεσμα μια σύνθεση αντισώματος αρκετά καθαρή για φαρμακευτικές χρήσεις. Οι μέθοδοι που περιγράφονται εδώ περιλαμβάνουν μείωση / απενεργοποίηση ιού του pΗ, υπερδιήθηση / διαδιήθηση, χρωματογραφία συγγένειας (π.χ. χρωματογραφία συγγένειας πρωτεΐνης Α), χρωματογραφία ανταλλαγής ιόντων και υδρόφοβη χρωματογραφία. Περαιτέρω, η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν ένα ή περισσότερα αντισώματα της παρούσας εφεύρεσης.
CY20201100781T 2009-10-20 2020-08-21 Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α CY1123952T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25341109P 2009-10-20 2009-10-20
PCT/US2010/053388 WO2011050071A2 (en) 2009-10-20 2010-10-20 Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
EP10777144A EP2491055A2 (en) 2009-10-20 2010-10-20 Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography

Publications (1)

Publication Number Publication Date
CY1123952T1 true CY1123952T1 (el) 2022-03-24

Family

ID=43900936

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100781T CY1123952T1 (el) 2009-10-20 2020-08-21 Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α

Country Status (27)

Country Link
US (5) US8491904B2 (el)
EP (2) EP2491055A2 (el)
JP (1) JP5914342B2 (el)
KR (2) KR101830596B1 (el)
CN (2) CN104744560A (el)
AU (1) AU2010310748C1 (el)
BR (1) BR112012009289B8 (el)
CA (1) CA2775595A1 (el)
CY (1) CY1123952T1 (el)
DK (1) DK3037104T3 (el)
ES (1) ES2813398T3 (el)
HR (1) HRP20201118T1 (el)
HU (1) HUE053489T2 (el)
IL (1) IL218897A (el)
IN (1) IN2012DN02778A (el)
LT (1) LT3037104T (el)
MX (2) MX2012004711A (el)
NZ (2) NZ627668A (el)
PL (1) PL3037104T3 (el)
PT (1) PT3037104T (el)
RS (1) RS60577B1 (el)
RU (1) RU2603055C2 (el)
SG (1) SG10201406713XA (el)
SI (1) SI3037104T1 (el)
TW (1) TWI515202B (el)
WO (1) WO2011050071A2 (el)
ZA (1) ZA201202720B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2615115A3 (en) * 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
CA2775595A1 (en) 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
KR101619865B1 (ko) 2010-07-30 2016-05-11 이엠디 밀리포어 코포레이션 크로마토그래피 매질
EP3235508B1 (en) * 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
EP2820149A1 (en) * 2012-02-27 2015-01-07 Biogen Idec MA Inc. High-throughput method for sialic acid quantitation
PL2970378T3 (pl) * 2013-03-15 2021-12-06 Biogen Ma Inc. Chromatografia oddziaływań hydrofobowych białek w warunkach bez soli
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
JP6141524B2 (ja) 2013-07-12 2017-06-07 メルク パテント ゲーエムベーハー 活性炭を用いた標的タンパク質含有サンプルからのフラグメントの除去
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JPWO2015041218A1 (ja) * 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
CN105017418B (zh) * 2014-03-27 2021-02-23 上海药明康德新药开发有限公司 单克隆抗体纯化工艺方法
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
KR102162753B1 (ko) 2014-12-08 2020-10-07 이엠디 밀리포어 코포레이션 혼합층 이온 교환 흡착제
PL3334747T3 (pl) 2015-08-13 2024-04-02 Amgen Inc. Naładowana filtracja wgłębna białek wiążących antygen
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
KR102460040B1 (ko) * 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
KR102511050B1 (ko) 2016-08-16 2023-03-17 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
CA3039788A1 (en) 2016-10-25 2018-05-03 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
KR102140693B1 (ko) * 2017-04-14 2020-08-05 에이치케이이노엔 주식회사 양이온 교환 크로마토그래피를 이용한 유사항체 정제 방법
ES2887046T3 (es) * 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
JPWO2020022363A1 (ja) * 2018-07-25 2021-08-02 第一三共株式会社 抗体−薬物コンジュゲートの効果的な製造方法
CN110818789B (zh) * 2018-08-07 2023-02-28 三生国健药业（上海）股份有限公司 一种高纯度食蟹猴白细胞介素17a的纯化方法
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
TW202112801A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
WO2021021260A1 (en) * 2019-08-01 2021-02-04 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
MY190626A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115003683A (zh) * 2020-01-17 2022-09-02 瑞泽恩制药公司 用于病毒清除的疏水相互作用色谱
CN112326966A (zh) * 2020-11-02 2021-02-05 杭州昱鼎生物科技有限公司 一种新型冠状病毒抗原的快速检测试剂盒及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (el)
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DE4041205A1 (de) 1990-12-21 1992-06-25 Schloemann Siemag Ag Verfahren und anlage zum auswalzen von warmbreitband aus stranggegossenen duennbrammen
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5457178A (en) * 1993-07-07 1995-10-10 Fmc Corporation Insecticidally effective spider toxin
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP0871436A4 (en) * 1995-06-30 1999-10-20 Smithkline Beecham Corp USE OF STAT 6 SH2 DOMAINE-SPECIFIC COMPOUNDS FOR TREATING ALLERGIC REACTIONS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
US7646782B1 (en) 2001-07-30 2010-01-12 Primrose Donald R Data link/physical layer packet buffering and flushing
WO2004026427A2 (en) * 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
WO2004076485A1 (en) * 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
ES2418830T3 (es) 2003-10-27 2013-08-16 Wyeth Llc Retirada de agregados de alto peso molecular usando cromatografía de hidroxiapatita
DE102004027816A1 (de) * 2004-06-08 2006-01-05 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von Erythropoietin
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB2430883B (en) 2005-09-30 2008-03-19 Cambridge Antibody Tech Interleukin-13 antibody composition
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
WO2007123961A2 (en) * 2006-04-20 2007-11-01 Wyeth Purification processes for isolating purified vesicular stomatitis virus from cell culture
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
EP3339445B1 (en) * 2006-09-08 2020-07-15 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
AU2009307737B2 (en) * 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
KR20110139216A (ko) * 2009-03-11 2011-12-28 와이어쓰 엘엘씨 소형 모듈형 면역약제 단백질의 정제 방법
CA2775595A1 (en) 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography

Also Published As

Publication number Publication date
EP3037104A1 (en) 2016-06-29
IL218897A (en) 2016-03-31
KR101830596B1 (ko) 2018-02-22
MX2012004711A (es) 2012-05-23
AU2010310748C1 (en) 2015-11-26
US20110206687A1 (en) 2011-08-25
LT3037104T (lt) 2020-09-10
ES2813398T3 (es) 2021-03-23
CN104744560A (zh) 2015-07-01
BR112012009289A8 (pt) 2017-12-05
JP5914342B2 (ja) 2016-05-11
HRP20201118T1 (hr) 2020-10-30
WO2011050071A2 (en) 2011-04-28
NZ627668A (en) 2016-03-31
US20130287771A1 (en) 2013-10-31
PL3037104T3 (pl) 2020-11-16
BR112012009289B8 (pt) 2021-05-25
WO2011050071A3 (en) 2011-09-15
BR112012009289A2 (pt) 2017-04-04
IL218897A0 (en) 2012-06-28
KR20170136649A (ko) 2017-12-11
US20180230210A1 (en) 2018-08-16
HUE053489T2 (hu) 2021-06-28
US9975948B2 (en) 2018-05-22
DK3037104T3 (da) 2020-07-20
RU2012120751A (ru) 2013-11-27
PT3037104T (pt) 2020-07-07
SG10201406713XA (en) 2014-11-27
NZ599100A (en) 2014-07-25
CN102711828B (zh) 2015-06-17
US9266950B2 (en) 2016-02-23
RU2603055C2 (ru) 2016-11-20
AU2010310748A1 (en) 2012-04-19
MX341136B (es) 2016-08-09
EP3037104B1 (en) 2020-05-27
ZA201202720B (en) 2012-12-27
US20220340656A1 (en) 2022-10-27
BR112012009289B1 (pt) 2021-01-05
SI3037104T1 (sl) 2020-10-30
US11390668B2 (en) 2022-07-19
IN2012DN02778A (el) 2015-09-18
US20160130339A1 (en) 2016-05-12
CN102711828A (zh) 2012-10-03
JP2013508387A (ja) 2013-03-07
TWI515202B (zh) 2016-01-01
AU2010310748B2 (en) 2015-05-21
US8491904B2 (en) 2013-07-23
EP2491055A2 (en) 2012-08-29
CA2775595A1 (en) 2011-04-28
TW201125876A (en) 2011-08-01
KR20120101002A (ko) 2012-09-12
RS60577B1 (sr) 2020-08-31

Similar Documents

Publication Publication Date Title
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
AU2016222301A1 (en) Isolation and purification of antibodies using Protein A affinity chromatography
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
CY1119069T1 (el) Σκευασματα αντισωματων υψηλης συγκεντρωσης δια παραπομπη προς συναφεις εφαρμογες
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201171494A1 (ru) Миметики белка smac
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
AR095432A1 (es) Proteínas de unión a antígeno
CO6612194A2 (es) Métodos de purificaciñon de adamts 13 y otras proteinas recombinantes y sus composiciones
CU24058B1 (es) Antagonistas de pcsk9
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
EA200702193A1 (ru) Гликозилирование белков